Global Cholera Vaccine Market - By Product Type: Killed Oral Cholera Vaccines (OCVs), Live Attenuated Oral Vaccines, Parenteral (Injectable) Vaccines (limited use); By Application: Outbreak Control, Traveler Immunization, Endemic Population Immunization, Military and Disaster Response; By End User: Government & Public Health Agencies, NGOs & International Organizations (WHO, UNICEF), Hospitals & Clinics, Traveler Health Clinics; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
1 | Market Overview
The global cholera vaccine market is experiencing significant growth, fueled by increasing demand for disease prevention in endemic regions, refugee camps, and disaster-prone areas. Cholera, caused by Vibrio cholerae, continues to be a major public health threat in low-income regions with poor water sanitation. Vaccines play a vital role in controlling outbreaks and reducing mortality.
Market growth is driven by increased World Health Organization (WHO) stockpile funding, government immunization programs, and the development of oral vaccines that are easier to distribute in resource-limited settings. Advances in single-dose and heat-stable formulations are further speeding up adoption.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
0.27 |
Historical benchmark |
|
2024 |
0.43 |
Five-year CAGR 9.7% |
|
2031 |
1.02 |
Seven-year CAGR 12.8% |
The market is projected to more than double by 2031, driven by expanded vaccination initiatives and public health investments.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The cholera vaccine market is moderately consolidated with key manufacturers supplying both public and private sectors, primarily focused on oral vaccines.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Products |
|
EuBiologics Co., Ltd. |
32% |
Euvichol®, Euvichol-Plus® |
|
Valneva SE |
25% |
Dukoral® (oral vaccine) |
|
Shantha Biotechnics (Sanofi) |
17% |
Shanchol™ (oral vaccine) |
|
Emergent BioSolutions |
11% |
Vaxchora® (single-dose traveler vaccine) |
|
Others (Biological E, Indian Immunologicals, regional OEMs) |
15% |
Pipeline and local vaccines |
6 | Market Segmentation
By Product Type:
By Application:
By End User:
By Region:
7 | Strategic Outlook
Investments in next-generation oral vaccines, expansion of WHO stockpiles, AI-driven outbreak prediction systems, and the development of single-dose, temperature-stable formulations will drive future growth in the cholera vaccine market. Demand in endemic regions will continue to drive market growth.
Need help?
Chat with our team in a minute.